Boston Scientific Co. (NYSE:BSX) Shares Sold by Community Trust & Investment Co.

Community Trust & Investment Co. lowered its stake in Boston Scientific Co. (NYSE:BSX - Free Report) by 15.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 179,780 shares of the medical equipment provider's stock after selling 33,557 shares during the quarter. Community Trust & Investment Co.'s holdings in Boston Scientific were worth $16,058,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in BSX. Marshall Wace LLP boosted its holdings in shares of Boston Scientific by 115.9% during the 2nd quarter. Marshall Wace LLP now owns 6,720,480 shares of the medical equipment provider's stock worth $517,544,000 after purchasing an additional 3,608,158 shares during the last quarter. AustralianSuper Pty Ltd grew its holdings in shares of Boston Scientific by 4,292.3% in the third quarter. AustralianSuper Pty Ltd now owns 2,676,847 shares of the medical equipment provider's stock valued at $224,320,000 after purchasing an additional 2,615,903 shares during the period. Ameriprise Financial Inc. increased its position in Boston Scientific by 30.0% during the second quarter. Ameriprise Financial Inc. now owns 7,899,610 shares of the medical equipment provider's stock worth $608,349,000 after purchasing an additional 1,824,405 shares during the last quarter. State Street Corp raised its stake in Boston Scientific by 2.3% during the third quarter. State Street Corp now owns 62,846,328 shares of the medical equipment provider's stock worth $5,266,522,000 after purchasing an additional 1,389,172 shares during the period. Finally, Allspring Global Investments Holdings LLC boosted its holdings in Boston Scientific by 98.0% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 2,205,368 shares of the medical equipment provider's stock valued at $184,810,000 after purchasing an additional 1,091,561 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company's stock.

Insider Activity at Boston Scientific

In related news, Director Edward J. Ludwig sold 4,877 shares of the company's stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $91.63, for a total value of $446,879.51. Following the sale, the director now owns 39,398 shares in the company, valued at $3,610,038.74. This represents a 11.02 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP John Bradley Sorenson sold 4,119 shares of the business's stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $90.02, for a total value of $370,792.38. Following the sale, the executive vice president now owns 35,319 shares in the company, valued at approximately $3,179,416.38. The trade was a 10.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 29,989 shares of company stock worth $2,702,261 over the last 90 days. Company insiders own 0.50% of the company's stock.

Boston Scientific Stock Performance

Shares of NYSE:BSX traded up $1.22 during trading on Wednesday, reaching $96.87. The company had a trading volume of 5,328,843 shares, compared to its average volume of 5,361,992. Boston Scientific Co. has a fifty-two week low of $59.61 and a fifty-two week high of $97.36. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.48 and a quick ratio of 1.02. The stock's fifty day moving average price is $90.36 and its 200 day moving average price is $84.15. The firm has a market capitalization of $142.77 billion, a price-to-earnings ratio of 80.06, a price-to-earnings-growth ratio of 2.67 and a beta of 0.80.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, October 23rd. The medical equipment provider reported $0.63 EPS for the quarter, topping analysts' consensus estimates of $0.59 by $0.04. The company had revenue of $4.21 billion during the quarter, compared to the consensus estimate of $4.04 billion. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. Boston Scientific's quarterly revenue was up 19.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.50 EPS. As a group, equities research analysts predict that Boston Scientific Co. will post 2.46 EPS for the current year.

Wall Street Analysts Forecast Growth

BSX has been the topic of several analyst reports. Canaccord Genuity Group lifted their price target on shares of Boston Scientific from $98.00 to $101.00 and gave the company a "buy" rating in a research report on Monday, December 9th. Mizuho upped their price target on Boston Scientific from $100.00 to $110.00 and gave the company an "outperform" rating in a research note on Thursday, October 24th. Morgan Stanley raised their price objective on Boston Scientific from $92.00 to $100.00 and gave the stock an "overweight" rating in a research report on Thursday, October 24th. Royal Bank of Canada increased their target price on shares of Boston Scientific from $95.00 to $98.00 and gave the stock an "outperform" rating in a research note on Thursday, October 24th. Finally, Stifel Nicolaus boosted their price target on shares of Boston Scientific from $85.00 to $100.00 and gave the company a "buy" rating in a research note on Friday, October 18th. Three analysts have rated the stock with a hold rating, twenty have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $97.26.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.